PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT COMMUNICATION
MEMORANDUM
TO: Marcus Whitfield, Vice President, Global Tax — Penterra Pharmaceuticals Corp.
FROM: Leonard Cross, Responsible Partner, Tax Department; Sylvia Hartwell, Billing Partner, Tax Department — Calderwood & Harkness LLP
DATE: April 15, 2024
RE: Going-Forward Transfer Pricing Recommendations — TY 2021 Forward
MATTER NO.: 1018-00009
CC: Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp.
Right-click to update Table of Contents
I. Purpose and Executive Summary
This memorandum provides advisory recommendations to Penterra Pharmaceuticals Corp. ("PPC" or the "Company") for strengthening its transfer pricing positions, contemporaneous documentation, and intercompany arrangements for Tax Year ("TY") 2021 and all subsequent tax years. These recommendations are informed by, and draw directly upon, the lessons learned during the Internal Revenue Service ("IRS") Large Business & International Division ("LB&I") examination of TY 2017–2020, designated Exam Team LB&I-NE-TP-2022-00641 (the "Examination"), which was resolved through the IRS Office of Appeals on March 29, 2024.
On that date, PPC and the IRS executed an IRS Form 906 Closing Agreement (the "Closing Agreement"), bringing the Examination to a final and conclusive resolution. PPC achieved a highly favorable outcome in the settlement: the total settlement adjustment was $47.6 million, representing only 12.51% of the $380.4 million in total proposed adjustments that the IRS had asserted through its Notice of Proposed Adjustment ("NOPA"). Of equal significance, the IRS agreed to full abatement of the IRC § 6662(e) substantial valuation misstatement penalty, which had been proposed at approximately $15.98 million. The resulting total cash cost to PPC is approximately $12.84 million, comprised of federal income tax of $10.0 million and estimated interest of approximately $2.84 million. This compares favorably to a potential total exposure that exceeded $95 million had the IRS's positions been sustained in full, inclusive of penalty, tax, and interest.
When professional fees are included — Calderwood & Harkness LLP ("C&H") fees of $5,837,420, Whitmore Valuation Group ("Whitmore") fees of $2,146,800, and Thornbury & Keogh fees of approximately $341,200 — the fully loaded cost of the Examination to PPC was approximately $21.2 million. While this figure is not insignificant, it represents a fraction of the amounts at stake and confirms that PPC's investment in vigorous defense was warranted.
While the resolution validates the fundamental soundness of PPC's intellectual property ("IP") holding structure, its cost-sharing arrangement ("CSA") with Penterra Biopharma International DAC ("PBI"), and its royalty methodology for legacy compounds, the Examination identified specific areas of vulnerability that, if left unaddressed, could provide the IRS with greater leverage in future examination cycles. The IRS's active involvement of its Office of Chief Counsel during the Examination further signals that pharmaceutical IP structures remain a priority enforcement area, and PPC should anticipate continued scrutiny.
Addressing the vulnerabilities identified herein on a proactive and contemporaneous basis will significantly reduce audit risk, strengthen PPC's defensibility, and potentially allow for more efficient resolution of any future examinations. This memorandum covers three principal areas of recommendation:
(A) Documentation enhancements, including upgrades to contemporaneous transfer pricing documentation, benchmarking protocols, and document retention practices;
(B) CSA methodology and cost-sharing calibration, including refinements to the reasonably anticipated benefits calculation, cost pool composition, and legacy IP royalty rate analysis; and
(C) PBI operational substance and DEMPE functions, including governance, headcount, capital expenditure, and banking enhancements designed to fortify PBI's standing as an entity with genuine economic substance and autonomous decision-making authority.
This memorandum also addresses intercompany agreement maintenance, Tax Cuts and Jobs Act ("TCJA")-related considerations, audit preparedness strategies, financial reporting implications, and a phased implementation plan.
A companion memorandum addressing Advance Pricing Agreement ("APA") considerations, including the feasibility, costs, and strategic implications of pursuing a bilateral APA with the IRS and the Irish Revenue Commissioners, is being provided to PPC under separate cover concurrently herewith.
II. Background and Context
A. The PPC IP Structure
To situate the recommendations that follow, we briefly describe the relevant entities and intercompany arrangements that constitute PPC's international IP structure.
Penterra Pharmaceuticals Corp. PPC is a publicly traded specialty pharmaceutical and biotechnology company, listed on the Nasdaq Stock Market under the ticker symbol PPCA and identified by Employer Identification Number 22-3741856. PPC is headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. For the fiscal year ended December 31, 2020, PPC reported consolidated revenue of $6.82 billion and pre-tax income of $1.47 billion. PPC is the ultimate parent company of the global group and the original developer and owner of all pharmaceutical IP within the group.
Penterra Biopharma International DAC ("PBI"). PBI was incorporated on March 15, 2012, in Ireland as a designated activity company under Irish company law, with Irish Tax Reference Number 3218764T. PBI's registered office is located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI serves as the principal operating entity for the non-Americas territories, holding rights to exploit PPC's pharmaceutical IP outside the Americas under the CSA and legacy IP license described below.
Penterra Holdings Luxembourg S.à r.l. ("PHL"). PBI is 100% owned, indirectly, through PHL, a société à responsabilité limitée incorporated in Luxembourg (Registre de Commerce et des Sociétés B 168452), with its registered office at 14 rue Aldringen, L-1118 Luxembourg. PHL is treated as a disregarded entity for U.S. federal income tax purposes pursuant to Treasury Regulation § 301.7701-3, meaning that PBI's activities and income are attributed directly to PPC for U.S. tax purposes through PHL. PHL was organized as an intermediate holding entity for European corporate and regulatory purposes.
Penterra Manufacturing Ireland Ltd. ("PMI"). PMI (Companies Registration Office Number 512347) is an Irish-incorporated entity that operates a pharmaceutical manufacturing facility at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland. PMI operates under a contract manufacturing agreement with PBI pursuant to which PMI manufactures pharmaceutical products for PBI on a cost-plus basis, with an 8% markup on fully loaded costs. As of December 31, 2020, PMI employed approximately 620 personnel, including manufacturing, quality control, supply chain, and administrative staff.
Cost-Sharing Arrangement. Effective July 1, 2012, PPC and PBI entered into a Qualified Cost Sharing Arrangement under then-applicable Treasury Regulation § 1.482-7 (the "CSA"). Under the CSA, PBI co-funds PPC's research and development costs in exchange for the right to exploit the resulting pharmaceutical IP outside the Americas (defined as the United States, Canada, Mexico, and all countries in Central and South America). PPC retains exclusive rights to exploit the IP within the Americas. At the inception of the CSA, PBI made a lump-sum platform contribution transaction ("PCT") payment of $312 million to PPC, representing the arm's-length consideration for PBI's buy-in to the pre-existing intangible development activities and IP platform that PPC had developed prior to the CSA's effective date.
Legacy IP License. In addition to the CSA, PPC and PBI entered into a separate license agreement for certain pre-2012 pharmaceutical compounds (the "Legacy IP License"). Under the Legacy IP License, PBI pays PPC a royalty at a rate of 4.5% of net sales of legacy compounds in the non-Americas territories. This arrangement covers compounds that were already commercialized or in late-stage development as of the CSA's effective date and were therefore excluded from the CSA's prospective cost-sharing framework.
Key Products. PPC's product portfolio includes three principal products that were at issue during the Examination:
• Veritaxol (oncology): Global net sales of $3.12 billion for FY 2020, of which $1.34 billion was attributable to non-Americas markets. Veritaxol is PPC's largest product by revenue and was the product most heavily scrutinized during the Examination.
• Imvara (immunology): Global net sales of $1.87 billion for FY 2020, of which $0.79 billion was attributable to non-Americas markets. Imvara experienced significant growth in non-Americas markets during the TY 2017–2020 period.
• Cerulon (rare disease): Global net sales of $0.62 billion for FY 2020, of which $0.28 billion was attributable to non-Americas markets. Cerulon is a specialty product with a smaller but high-margin revenue base.
Collectively, these three products accounted for the substantial majority of the intercompany transactions and transfer pricing positions under review during the Examination.
B. Summary of IRS Examination and Resolution
The following summary of the Examination proceedings provides context for the specific vulnerabilities and corresponding recommendations discussed in the balance of this memorandum.
Examination Opening and Scope. The IRS opened the Examination on May 16, 2022, with the issuance of Letter 2205-A to PPC, advising that the IRS intended to examine PPC's federal income tax returns for TY 2017 through TY 2020. The Examination was conducted by LB&I's Northeast Transfer Pricing practice, under Exam Team designation LB&I-NE-TP-2022-00641. Over the course of the Examination, the IRS issued a total of 47 Information Document Requests ("IDRs") between June 2022 and September 2023, covering topics ranging from organizational structure and intercompany agreements to detailed financial models, revenue projections, employee interview requests, and benchmarking analyses.
IRS Primary Challenges. The IRS's proposed adjustments were based on four principal challenges to PPC's transfer pricing positions:
1. Cost-Sharing Ratios. The IRS asserted that PBI's cost-sharing percentages under the CSA were understated. The IRS's economist, Dr. Alan Washburne, proposed increasing PBI's cost-sharing percentages by 8 to 12 percentage points across the examination years, based on alternative reasonably anticipated benefits projections and a lower discount rate (7.2% weighted average cost of capital vs. PPC's 9.8%). This challenge resulted in proposed adjustments totaling $235.01 million across TY 2017–2020.
2. Legacy IP Royalty Rate. The IRS asserted that the 4.5% royalty rate under the Legacy IP License was below the arm's-length range and proposed increasing the rate to 11.0%. The IRS's position was based on an alternative comparable uncontrolled transaction ("CUT") analysis that identified license agreements purportedly more comparable to PPC's legacy IP than those identified in PPC's documentation. This challenge resulted in proposed adjustments totaling $188.04 million.
3. PBI Economic Substance / DEMPE Functions. The IRS asserted that PBI lacked sufficient economic substance and that the key Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") functions associated with PPC's pharmaceutical IP remained in the United States. Under this theory, the IRS argued that PBI was not entitled to the residual profits attributable to the non-Americas IP rights because PBI did not perform or control the economically significant functions generating those profits.
4. PCT Undervaluation. Although TY 2012 (the year of the PCT payment) was outside the Examination years, the IRS used its assertion that the $312 million PCT payment was substantially below arm's length (the IRS asserted the payment should have been $852 million) to support a recharacterization of the ongoing CSA and related arrangements during TY 2017–2020.
Total Proposed Adjustments. The IRS's total proposed adjustments were $380.4 million, computed as $235.01 million (CSA adjustments) plus $188.04 million (royalty adjustments) minus $42.65 million in correlative offsets. In addition, the IRS proposed a substantial valuation misstatement penalty under IRC § 6662(e) of approximately $15.98 million.
Procedural History. The IRS issued its NOPA on October 12, 2023, followed by the 30-Day Letter on November 8, 2023. PPC, through C&H, filed a formal Protest on December 22, 2023, setting forth PPC's factual and legal positions in opposition to each proposed adjustment. The Appeals Conference was held on February 28, 2024, at the IRS Office of Appeals in Manhattan, before Appeals Officer Noreen Castañeda.
Settlement. Following the Appeals Conference and subsequent negotiations, the parties executed the Closing Agreement on March 29, 2024. The settlement provided for a total adjustment of $47.6 million, allocated as follows: $11.2 million (TY 2017), $12.4 million (TY 2018), $12.8 million (TY 2019), and $11.2 million (TY 2020). The IRC § 6662(e) penalty was fully abated. The resulting federal income tax liability was $10.0 million, with estimated interest of approximately $2.84 million.
Total Cost to PPC. Including professional fees — C&H ($5,837,420), Whitmore Valuation Group ($2,146,800), and Thornbury & Keogh ($341,200, approximate) — the fully loaded cost of the Examination to PPC was approximately $21.2 million.
C. Key Vulnerabilities Identified During the Examination
Notwithstanding the favorable settlement result, the Examination exposed three areas where the IRS's arguments gained meaningful traction or where PPC's defense required significant effort and resources to overcome. These vulnerabilities inform the specific recommendations in Sections III through VIII of this memorandum.
discount Rate and Revenue Projections. The IRS's economist, Dr. Alan Washburne, challenged PPC's discount rate assumption — specifically, PPC's use of a 9.8% weighted average cost of capital ("WACC") versus the IRS's proposed 7.2% WACC — in the income-method analyses supporting both the PCT valuation and the reasonably anticipated benefits split that drives cost-sharing ratios. While PPC's WACC was ultimately found to be within the arm's-length range, the IRS's ability to mount this challenge was facilitated in part by PPC's limited contemporaneous documentation of the WACC derivation, including the specific assumptions regarding risk-free rate, equity risk premium, size premium, industry beta, and pharmaceutical-specific risk adjustments. Similarly, Dr. Washburne challenged PPC's revenue projections supporting the Americas versus non-Americas revenue split, asserting that PPC's projections systematically understated U.S.-source value and overstated the share of value attributable to non-Americas markets. The gap between projected and actual revenue splits in certain years provided the IRS with retrospective ammunition.
CUT Analysis for the Royalty Rate. The IRS's alternative CUT analysis for the legacy IP royalty rate relied on comparable license agreements that, while ultimately distinguishable on the basis of product type, therapeutic area, geographic scope, stage of development, and other comparability factors, required significant effort and expert rebuttal from Whitmore Valuation Group to overcome. PPC's existing CUT database of 14 comparable license agreements (interquartile range of 3.1%–6.8%, median 4.4%) supported PPC's 4.5% rate, but the IRS's alternative CUTs, which involved higher-value IP in comparable therapeutic areas, were not facially unreasonable. This underscored the importance of maintaining a robust, frequently refreshed CUT database and explicitly addressing anticipated comparability objections in the contemporaneous documentation.
Economic Substance and DEMPE. The IRS's challenge to PBI's economic substance and DEMPE functions, while ultimately unsuccessful, exploited identifiable gaps in the documentary evidence of PBI's autonomous decision-making. Certain PBI board minutes were characterized by the IRS as perfunctory or formulaic, lacking evidence of genuine deliberation. Additionally, reporting relationships between certain PBI personnel and their U.S.-based PPC counterparts were ambiguous in the documentary record, and the IRS argued that key decisions regarding IP protection (patent prosecution and defense), product development strategy, and pricing were in fact made by PPC personnel in Princeton Junction rather than by PBI personnel in Dublin. While C&H and Whitmore successfully rebutted these assertions through employee interviews, contemporaneous email evidence, and detailed functional analyses, the defense would have been considerably stronger had more rigorous documentation been maintained on a contemporaneous basis.
IRS Chief Counsel Involvement. It bears noting that the IRS Office of Chief Counsel participated actively in the Examination, with Attorney-Advisor Franklin Rosario and Senior Counsel Donna Hirabayashi involved in the development of the IRS's legal positions. This level of engagement signals that the IRS may continue to devote substantial resources to pharmaceutical IP structures in future examination cycles, and PPC should prepare accordingly.
III. Recommendations — Transfer Pricing Documentation Enhancements
A. Contemporaneous Documentation Under IRC § 6662(e)(3)(B)
PPC's existing transfer pricing documentation was prepared by Crestfield & Associates LLP ("Crestfield"), with Transfer Pricing Partner Susan Lam, CPA, and Engagement Partner Martin Ogilvy, CPA, serving as the principal contacts (Crestfield's offices are located at 1200 Avenue of the Americas, New York, NY 10036). Crestfield has served as PPC's transfer pricing documentation provider since TY 2013, when the CSA documentation was first required.
As noted above, PPC's existing Crestfield documentation proved adequate for penalty protection purposes during the Examination: the IRC § 6662(e) substantial valuation misstatement penalty was fully abated, and the IRS did not challenge the existence of documentation per se. However, the quality and depth of the documentation were tested at multiple points during the Examination, and C&H identified several areas where enhancements would materially strengthen PPC's position in future examination cycles. The abatement of the penalty is attributable in part to the existence of documentation that met the minimum statutory threshold; however, minimum compliance is not the standard PPC should aspire to for a structure of this magnitude and complexity.
Accordingly, C&H recommends the following specific enhancements to PPC's contemporaneous transfer pricing documentation practices:
Annual Update Cycle. Documentation should be prepared and finalized no later than the federal income tax return filing deadline (including extensions) for each tax year. Under IRC § 6662(e)(3)(B) and the corresponding Treasury Regulations, documentation that is prepared or completed after the filing date may not be treated as "contemporaneous" for penalty-protection purposes. During the Examination, the IRS raised a threshold challenge to the contemporaneity of certain documentation, noting that internal metadata on certain files suggested portions of the TY 2018 and TY 2019 documentation were completed after the extended filing deadline. While this challenge was ultimately not pursued to its conclusion (the penalty was abated on other grounds in the settlement), it represents a vulnerability that should be eliminated. C&H recommends that PPC establish a hard internal deadline requiring Crestfield to deliver final documentation no later than 30 days before the extended filing deadline, with a documented review and sign-off by PPC's tax department (Marcus Whitfield or designee) confirming that the documentation is complete and accurate.
Enhanced Functional Analysis. Each year's transfer pricing documentation should include a detailed functional analysis of PBI, prepared fresh annually — not merely a boilerplate carryforward of the prior year's analysis with updated financial data. The functional analysis is the foundation upon which the entire transfer pricing methodology rests, and it was the document most intensively scrutinized by the IRS during the Examination. Going forward, the annual functional analysis should document, at a minimum, the following elements with respect to PBI's operations for the year in question:
• Headcount changes (new hires, departures, promotions, organizational restructurings), broken down by function (commercial, regulatory, medical affairs, quality, finance, legal, general management);
• Regulatory submissions filed by or on behalf of PBI during the year, including marketing authorization applications, variations, renewals, and pharmacovigilance reports, identifying the jurisdictions involved and PBI's role in each submission;
• Pricing decisions made by PBI for non-Americas markets, including evidence of PBI's autonomous authority over pricing (as distinct from pricing guidance or directives from PPC);
• Capital expenditures incurred by PBI during the year, including investments in office facilities, IT systems, regulatory infrastructure, and other operational assets;
• New market entries or exits during the year, including the commercial rationale, due diligence performed by PBI, and the decision-making process;
• Distribution agreements entered into, amended, or terminated by PBI during the year; and
• Material contracts entered into by PBI with third parties (other than intercompany agreements), including consulting engagements, marketing partnerships, and regulatory advisory relationships.
Refreshed Benchmarking Data. The CUT and CPM/TNMM (Comparable Profits Method / Transactional Net Margin Method) databases that underlie PPC's transfer pricing analyses should be refreshed annually. During the Examination, Whitmore Valuation Group identified 14 CUT comparable license agreements with an interquartile range of 3.1% to 6.8% and a median royalty rate of 4.4%, supporting PPC's 4.5% Legacy IP License rate. Additionally, Whitmore identified 22 CPM/TNMM comparables for the benchmarking of PBI's profitability. Both sets of comparables should be updated annually with current data sourced from publicly available databases (Vireo Health IT, Sundial Health IT, BvD Orbis, Fenmore Services Inc., and other recognized sources). New license agreements or comparable entities that have entered the public domain should be identified and evaluated for inclusion. Conversely, agreements that have expired, been terminated, or otherwise become stale should be flagged and, where appropriate, excluded with a documented rationale for their removal.
discount Rate and WACC Documentation. The WACC assumptions underlying the reasonably anticipated benefits calculations and any income-method validation (including any cross-checks using discounted cash flow models) should be documented with granular, current market data each year. As noted in Section II.C above, the IRS's ability to credibly argue for a 7.2% WACC — nearly 260 basis points below PPC's 9.8% — was enabled in part by PPC's limited contemporaneous documentation of its WACC derivation. Going forward, the WACC documentation should include, at a minimum:
• The risk-free rate used and its source (e.g., U.S. Treasury yield curve data for the relevant period);
• The equity risk premium and the source relied upon (e.g., Beaumont Advisors publications);
• The size premium, if applicable, and its derivation;
• The industry beta (levered and unlevered), with identification of the comparable company set used to derive the beta;
• The pharmaceutical-specific risk adjustment, if any, with documentation of the basis for the adjustment (e.g., regulatory risk, pipeline risk, reimbursement risk);
• The cost of debt, including the reference rate and credit spread applicable to PPC's outstanding indebtedness; and
• The capital structure assumptions (debt-to-equity ratio) and their basis in PPC's actual or target capital structure.
This documentation should be prepared by Whitmore Valuation Group (or a comparable qualified valuation firm) on an annual basis and incorporated into the contemporaneous transfer pricing report.
Revenue Projection Methodology. The methodology for projecting Americas versus non-Americas revenue splits — which serve as the primary allocation key for the reasonably anticipated benefits calculation driving cost-sharing ratios — should be formally documented each year. During the Examination, the IRS challenged PPC's revenue projections as systematically biased in favor of non-Americas growth, thereby inflating PBI's share of reasonably anticipated benefits and reducing PBI's cost-sharing percentage below what the IRS considered arm's length. Going forward, the documentation should explicitly link revenue projections to PPC's internal budgeting and strategic planning processes, product lifecycle analyses (including patent expiry dates, expected generic entry timelines, and biosimilar competition), market-by-market forecasts prepared by PPC's and PBI's commercial organizations, and any relevant external market data or analyst projections. Where PPC's internal projections diverge from external consensus estimates, the basis for the divergence should be documented.
B. Coordination Between Crestfield and Calderwood & Harkness
C&H recommends establishing a formal annual coordination protocol between Crestfield (as PPC's transfer pricing documentation preparer) and C&H (as PPC's legal advisor on transfer pricing matters). Under this protocol, C&H would review Crestfield's draft annual transfer pricing documentation for legal sufficiency before PPC finalizes and signs off on the documentation. This review would encompass, at a minimum:
• The legal characterization of intercompany transactions and the selection of the best method under Treasury Regulation § 1.482-1(c);
• The selection and characterization of comparable transactions and entities, with particular attention to CUT comparables in light of the IRS's reliance on Dr. Washburne's alternative CUT selections during the Examination;
• The consistency of the documentation with the terms of PPC's intercompany agreements, including the CSA, Legacy IP License, and PMI manufacturing agreement;
• The adequacy of the functional analysis as a defense against potential economic substance and DEMPE challenges; and
• The sufficiency of the documentation for penalty-protection purposes under IRC § 6662(e)(3)(B) and the corresponding Treasury Regulations.
This coordination protocol should be memorialized in a written engagement letter or protocol memorandum and should specify timelines, deliverables, and points of contact at each firm. The incremental cost of C&H's review is expected to be modest relative to the risk mitigation it provides.
C. Document Retention and Organization
C&H recommends that PPC implement a dedicated transfer pricing document repository within PPC's existing records-management system (or, if necessary, a purpose-built repository). This repository should serve as a centralized, indexed, and readily searchable archive for all documents relevant to PPC's intercompany arrangements and transfer pricing positions, including but not limited to:
• All intercompany agreements (CSA, Legacy IP License, PMI manufacturing agreement, and any other intercompany contracts), including all amendments, supplements, and side letters;
• PBI board minutes and resolutions, including minutes of all board meetings and written resolutions in lieu of meetings;
• PBI organizational charts and personnel records (headcount data, job descriptions, CVs of senior management, reporting-line documentation);
• Regulatory filings made by or on behalf of PBI in non-Americas jurisdictions;
• Financial models, revenue projections, budgets, and strategic plans used in transfer pricing analyses;
• Valuation reports and supporting workpapers prepared by Whitmore Valuation Group or other economists;
• Transfer pricing reports prepared by Crestfield & Associates;
• Correspondence with the IRS (Letters, IDRs, responses, NOPAs, protests) from prior examination cycles; and
• Banking and treasury records demonstrating PBI's independent financial operations.
The importance of this recommendation is underscored by PPC's experience during the Examination. Over the course of the 47-IDR process, which spanned approximately 15 months, some documents required significant time to locate and produce, resulting in delays, follow-up IDRs, and additional professional fees. In several instances, documents were located in the personal files of individual PPC or PBI employees rather than in centralized repositories, and certain email communications relevant to PBI's decision-making had to be reconstructed from backup systems. Proactive organization will reduce response times and costs in any future examination and will project an image of professionalism and preparedness to the examining team.
IV. Recommendations — CSA Methodology and Cost-Sharing Calibration
A. Reasonably Anticipated Benefits and Cost-Sharing Ratios
Under the CSA, PBI's share of the qualified R&D cost pool is determined by reference to PBI's share of the reasonably anticipated benefits ("RABs") from the intangible development activities, consistent with Treasury Regulation § 1.482-7(e). For TY 2017 through TY 2020, PBI's cost-sharing percentages ranged from 38.2% to 42.7%, reflecting the increasing share of PPC's pharmaceutical revenues attributable to non-Americas markets as Veritaxol, Imvara, and Cerulon expanded their international commercial footprint.
The IRS proposed increasing PBI's cost-sharing percentages by 8 to 12 percentage points (to a range of 48.2% to 53.7%), resulting in proposed adjustments of $235.01 million. The IRS's primary basis for this adjustment was its assertion that PPC's revenue projections — which serve as the allocation key for the RAB calculation — systematically understated U.S.-source value and that PPC's discount rate (9.8% WACC) was too high, which had the effect of reducing the present value of U.S. benefits relative to non-Americas benefits in the income-method cross-check.
While PPC's cost-sharing ratios were ultimately sustained at the Appeals level (with a modest adjustment reflected in the $47.6 million settlement), the IRS's arguments were not without force, and the following enhancements are recommended to strengthen PPC's position going forward:
Dual-Methodology Validation. In addition to the revenue-based RAB calculation required by Treasury Regulation § 1.482-7, C&H recommends that PPC prepare a supplementary analysis using an alternative allocation key as a cross-check. Appropriate alternative methodologies include an operating profit split analysis (allocating RABs based on projected operating profit rather than revenue) or a contribution analysis (allocating RABs based on each party's relative contributions to value creation, including personnel, assets, and risk-bearing). The purpose of this dual-methodology approach is twofold: first, it demonstrates analytical rigor and good faith on the part of PPC; second, it preempts the IRS's recurring argument that revenue-based RABs inherently understate U.S.-source value because the Americas market (particularly the U.S.) typically generates higher per-unit margins than non-Americas markets due to pricing dynamics, reimbursement structures, and competitive conditions. If the alternative methodology produces results that are consistent with the revenue-based RAB calculation, it provides powerful corroborative support; if it produces divergent results, the documentation should explain the divergence and articulate why the revenue-based approach remains the most reliable method under the specific facts and circumstances.
Annual Reconciliation of Projections to Actuals. Each year, PPC should prepare a formal reconciliation comparing the projected revenue splits used in the prior year's cost-sharing calculation to the actual revenue results for that year. This reconciliation should identify and quantify any material deviations between projected and actual results, analyze the sources of the deviations (e.g., faster-than-expected Veritaxol uptake in European markets, currency effects, regulatory delays, competitive dynamics), and document whether the deviations reflect systematic bias in the projection methodology or one-time factors. Where the reconciliation reveals material and recurring deviations, PPC should consider whether adjustments to the projection methodology are warranted and, if appropriate, implement true-up adjustments to the cost-sharing ratios. During the Examination, the IRS closely examined the gap between projected and actual revenue splits and used retrospective data to argue that PPC's projections were consistently biased. A formal reconciliation process, documented contemporaneously, would have significantly blunted this line of attack.
Sensitivity Analysis. Each year's transfer pricing documentation should include a sensitivity analysis showing how cost-sharing ratios would change under alternative revenue assumptions. At a minimum, this analysis should present three scenarios: a base case (using management's best-estimate projections), an upside case (assuming more favorable non-Americas revenue growth), and a downside case (assuming less favorable non-Americas revenue growth or stronger Americas performance). The sensitivity analysis should quantify the dollar impact on cost-sharing payments under each scenario and should demonstrate that PPC's selected cost-sharing ratio falls within a defensible range under reasonable alternative assumptions. This analysis demonstrates good faith and analytical rigor, and it provides a ready response to IRS challenges that PPC's projections are unreasonably optimistic or pessimistic regarding any particular market.
B. Qualified R&D Cost Pool Composition
PPC's total qualified R&D costs included in the CSA cost pool grew from $487.3 million in TY 2017 to $598.4 million in TY 2020, reflecting increased investment in late-stage clinical development for Veritaxol and Imvara, as well as early-stage pipeline activities. The IRS scrutinized the composition of the cost pool through IDR No. 6 (issued July 28, 2022) and multiple follow-up IDRs, challenging the inclusion or exclusion of specific cost categories.
C&H recommends the following enhancements to PPC's cost pool determination process:
Formal Annual Determination. PPC should prepare a formal annual determination of which costs qualify for inclusion in the CSA cost pool, with clear and detailed documentation of the inclusion and exclusion criteria applied under Treasury Regulation § 1.482-7(d). This determination should be reviewed by both Crestfield and C&H and should be incorporated into the contemporaneous transfer pricing documentation. The determination should address, at a minimum, the following cost categories that the IRS scrutinized during the Examination: direct R&D labor costs, contract research organization ("CRO") fees, clinical trial costs, regulatory submission costs, pre-clinical research costs, R&D facility overhead, and R&D-related depreciation and amortization.
Stock-Based Compensation. Particular attention should be given to the treatment of stock-based compensation ("SBC") costs in the CSA cost pool. The U.S. Tax Court's decision in Altera Corp. v. Commissioner, 145 T.C. 91 (2015), which was reversed by the Ninth Circuit in 2019 and for which certiorari was denied by the Supreme Court in 2020, addressed the requirement to include SBC in cost-sharing pools under Treasury Regulation § 1.482-7A(d)(2). While the procedural posture and precedential effect of Altera continue to evolve, PPC should ensure that its treatment of SBC in the cost pool is consistent with current regulatory requirements and is clearly documented and defensible. Given PPC's significant use of stock-based compensation for R&D personnel, the dollar amounts at stake are material.
Americas-Only Costs. PPC should implement a systematic process for identifying and excluding from the CSA cost pool any costs that are attributable solely to Americas territory activities. Under the CSA, costs that benefit only the Americas territory should not be shared with PBI. During the Examination, the IRS questioned whether certain marketing-related costs and post-launch commercial activities included in the cost pool had any nexus to the intangible development activities covered by the CSA. A clear and documented exclusion methodology will reduce this vulnerability.
C. PCT Valuation Maintenance
While the original $312 million PCT payment (effective July 1, 2012) was found to be within the arm's-length range of $278 million to $361 million as determined by Whitmore Valuation Group's discounted cash flow analysis at a 9.8% WACC, the IRS's assertion that the PCT should have been $852 million — based on a lower WACC of 7.2% and more optimistic revenue projections — created significant examination risk and was a central element of the IRS's strategy for recharacterizing the ongoing CSA arrangements.
Although the PCT payment itself was made in TY 2012 and was outside the scope of the TY 2017–2020 Examination, the IRS's arguments regarding PCT undervaluation were not merely academic: the IRS used its PCT challenge as a basis for asserting that the entire CSA was not calibrated at arm's length from inception, thereby supporting its proposed adjustments to ongoing cost-sharing ratios and its economic substance / DEMPE challenge.
For any future CSA modifications, expansions, new intangible development activities brought within the CSA scope, or other transactions that would constitute new platform contribution transactions, C&H recommends the following:
• Contemporaneous Valuation. Engage Whitmore Valuation Group (Dr. Helena Vasquez, Managing Director; 200 Ashbury Asset Advisors, Suite 700, Boston, MA 02109) or an equivalent qualified economist contemporaneously to prepare full income-method and discounted cash flow valuations for any new PCT or buy-in payment. The valuation should be completed and documented before or concurrently with the execution of the relevant transaction, not retrospectively.
• Granular WACC Support. Document the WACC derivation with the level of granularity described in Section III.A above, including all individual components and data sources. This documentation should be sufficient to withstand the type of challenge mounted by Dr. Washburne during the Examination.
• Preservation of Underlying Assumptions. Preserve the revenue projections, discount rate assumptions, terminal value calculations, and all supporting workpapers that underlie any PCT or buy-in payment valuation. These materials should be maintained in the dedicated transfer pricing document repository recommended in Section III.C and should be readily accessible in the event of a future examination.
D. Legacy IP Royalty Rate
The 4.5% royalty rate under the Legacy IP License was within the arm's-length range established by PPC's CUT analysis (interquartile range of 3.1% to 6.8%, median of 4.4%). However, the IRS's proposed increase to 11.0% — based on alternative CUT comparables involving purportedly higher-value IP in comparable therapeutic areas — resulted in proposed adjustments of $188.04 million. While the IRS's comparables were ultimately distinguishable, the magnitude of the proposed adjustment and the effort required to rebut the IRS's CUT analysis highlight the need for continued vigilance.
It is worth noting that non-Americas legacy compound net sales are on a declining trajectory, from $814.6 million in TY 2017 to $624.1 million in TY 2020, reflecting natural product lifecycle dynamics as older compounds face generic competition and loss of exclusivity. This trend is expected to continue, and the declining revenue base may reduce the materiality of the legacy royalty rate as a transfer pricing issue in future examination cycles. Nevertheless, the royalty rate remains a live issue for as long as the Legacy IP License generates meaningful payments, and the following steps are recommended:
Periodic Reassessment. Consider whether the royalty rate should be periodically reassessed — and potentially adjusted — as the legacy product portfolio evolves. Factors that may warrant reassessment include the entry of generic competitors in key non-Americas markets, the loss of regulatory exclusivity or patent protection for specific compounds, changes in the therapeutic standard of care that reduce a legacy compound's commercial value, and the introduction of new PPC products that compete with or cannibalize legacy compound sales. Any reassessment should be documented as an arm's-length determination supported by updated benchmarking data.
Annual CUT Database Refresh. The CUT database should be refreshed annually as described in Section III.A. Specifically, the 14 CUT comparable license agreements identified by Whitmore should be reviewed each year to confirm their continued comparability. Agreements that have been terminated, materially amended, or otherwise become non-comparable should be flagged, and the documentation should explain why they are retained or excluded. New license agreements that have entered the public domain should be evaluated for inclusion.
Explicit Rebuttal of IRS Comparability Objections. The annual transfer pricing documentation should explicitly address the specific comparability objections raised by the IRS during the TY 2017–2020 Examination. In particular, the IRS argued that PPC's selected CUTs involved IP of lower value than PPC's flagship compounds (particularly Veritaxol, which is a blockbuster oncology product with limited direct competition). The documentation should explain why PPC's CUTs remain the most reliable comparables notwithstanding any differences in the underlying IP's commercial value, or, alternatively, should incorporate adjustments for such differences. This proactive rebuttal will prevent the IRS from recycling the same arguments in future examination cycles.
V. Recommendations — PBI Operational Substance and DEMPE Functions
A. Overview of the IRS's Economic Substance / DEMPE Challenge
During the Examination, the IRS asserted that PBI lacked sufficient economic substance and that the key DEMPE functions — Development, Enhancement, Maintenance, Protection, and Exploitation — associated with PPC's pharmaceutical IP remained concentrated in the United States, specifically at PPC's headquarters in Princeton Junction, New Jersey. Under this theory, the IRS argued that PBI was essentially a shell entity or conduit, and that the economic returns attributable to non-Americas IP exploitation should properly be taxed in the United States.
C&H and Whitmore successfully rebutted the IRS's economic substance and DEMPE challenge through a comprehensive evidentiary showing, including the following key facts:
• PBI employed 185 individuals as of December 31, 2020, up from 52 employees at the time of its incorporation in March 2012. The employee base included senior commercial, regulatory, medical affairs, quality, finance, and legal personnel.
• PBI's board of directors held 42 meetings in Dublin over the TY 2017–2020 period, an average of more than 10 meetings per year, demonstrating active governance and decision-making.
• PBI incurred cumulative regulatory expenditures of €47.2 million during TY 2017–2020, including costs associated with marketing authorization applications, label extensions, variations, pharmacovigilance reporting, and post-marketing surveillance across dozens of non-Americas jurisdictions.
• PBI occupied approximately 18,000 square feet of office space at Sandyford Business Park in Dublin, with dedicated functional areas for its commercial, regulatory, medical affairs, and administrative teams.
• PBI maintained independent pricing authority across 68 country markets outside the Americas, with documented evidence of autonomous pricing decisions tailored to local market conditions, reimbursement frameworks, and competitive dynamics.
• PBI maintained local banking relationships with Glenmore Bank Ireland plc, with separate bank accounts for revenue collection, disbursements, and intercompany settlements.
• PBI was led by Managing Director Aidan Naughton, an experienced pharmaceutical executive based in Dublin with direct responsibility for PBI's operations and strategy.
Despite the success of PPC's defense, the IRS's challenge was not frivolous, and certain documentary gaps provided the IRS with footholds. The following enhancements are designed to eliminate those gaps and further strengthen PBI's position as an entity with genuine economic substance and autonomous decision-making authority.
B. Headcount and Human Capital
PBI's headcount grew from 52 employees at the time of its incorporation in 2012 to 185 employees as of December 31, 2020. This growth was an important element of PPC's defense, demonstrating that PBI has progressively built the operational capacity necessary to perform its DEMPE functions. C&H recommends the following:
Continued Organic Growth. PBI should continue to grow its headcount organically, targeting a ratio that reflects PBI's expanding non-Americas revenue base and commercial responsibilities. The headcount growth should be concentrated in the functions that are most relevant to PBI's DEMPE profile — specifically, commercial and marketing, regulatory affairs, medical affairs, quality assurance, and strategic planning. While there is no specific numerical threshold that constitutes "sufficient" headcount, PBI's staffing levels should be consistent with the scope and complexity of its operations and should be benchmarked, where possible, against comparable pharmaceutical entities operating in similar markets.
Elimination of Informal U.S. Direction. All key DEMPE functions identified in PBI's functional analysis should be staffed by PBI employees or PBI-contracted resources who are located in Ireland, not by U.S.-based PPC personnel operating on secondment or providing informal direction. During the Examination, the IRS identified certain instances where PPC U.S. personnel appeared to be providing guidance or direction to PBI personnel on matters that the functional analysis characterized as PBI's autonomous activities. While the evidence showed that this guidance was advisory rather than directive, the ambiguity in the documentary record weakened PPC's position. Going forward, PBI should ensure that its personnel have clear authority over their respective functions and that any input from PPC U.S. personnel is documented as non-binding advice or information-sharing under a properly structured intercompany services agreement.
Personnel Documentation. The qualifications, experience levels, and decision-making authority of senior PBI personnel should be thoroughly documented and maintained in the transfer pricing document repository. During the Examination, C&H conducted interviews of 12 key PBI employees (conducted by C&H associates Garrett Simmons and Leila Nazari in August and September 2022) to prepare for potential IRS interviews of PBI personnel. These interviews revealed some ambiguity in reporting lines — specifically, certain PBI personnel described their reporting relationships in terms that suggested dual reporting to both PBI management (Aidan Naughton) and their U.S. counterparts at PPC. While the C&H interview preparation resolved these ambiguities before the IRS's own interviews, the underlying organizational structure should be clarified to ensure that PBI employees report to PBI management for all operational decisions. PPC U.S. counterparts may serve as functional mentors, technical resources, or information sources, but the chain of command for decision-making should run exclusively through PBI's management structure.
C. Board Governance and Decision-Making
The 42 board meetings held in Dublin over TY 2017–2020 were critical evidence in PPC's defense against the economic substance / DEMPE challenge. Going forward, C&H recommends the following enhancements to PBI's governance practices:
Meeting Frequency and Location. PBI should maintain at least quarterly board meetings, with special sessions convened as needed to address significant transactions, strategic decisions, or other matters requiring board-level approval. All board meetings should be held in Dublin, Ireland. If exigent circumstances require a meeting to be held by teleconference or videoconference, the meeting should nonetheless be organized and chaired from Dublin, with the majority of directors participating from Ireland, and the minutes should reflect these facts.
Substantive Minutes. Board minutes should capture substantive discussion and deliberation, not merely record resolutions adopted. Specifically, the minutes should document the board's consideration and approval (or rejection) of the following matters, among others:
• Product pricing decisions for non-Americas markets, including the factors considered (market conditions, competitive landscape, reimbursement environment, health technology assessments) and the alternatives evaluated;
• Market entry and exit decisions, including the commercial and regulatory analysis supporting the decision;
• Significant capital expenditures proposed or approved by PBI;
• Regulatory strategy for non-Americas markets, including decisions regarding the timing and scope of regulatory submissions, responses to regulatory authority inquiries, and pharmacovigilance reporting;
• Distribution partner selection, evaluation, and management in non-Americas markets;
• Commercial strategy, including marketing campaigns, product launch plans, and key account management;
• Annual budgets and strategic plans for PBI's operations; and
• Intercompany transactions and agreements, including any amendments to the CSA, Legacy IP License, or PMI manufacturing agreement.
Avoidance of Perfunctory Minutes. The IRS cited certain PBI board minutes from the TY 2017–2020 period as lacking evidentiary value because they did not reflect genuine deliberation. Specifically, certain minutes consisted entirely of recitals that the board "reviewed and approved" certain matters without any description of the discussion, questions raised, alternatives considered, or basis for the decision. Going forward, PBI's board secretary (or C&H, if requested to assist in drafting) should ensure that minutes reflect the substance of the discussion, identify the information presented to the board, note any dissenting views or concerns raised, and articulate the rationale for the board's decision. This does not require verbatim transcription, but it does require more than formulaic language.
Independent Directors. C&H recommends that PBI consider adding one or two independent directors to its board. These should be Irish-resident individuals with relevant pharmaceutical, commercial, or regulatory expertise who can bring genuine independent judgment to PBI's governance. The presence of independent directors would further demonstrate PBI's autonomous governance and would provide an additional layer of evidence that PBI's board is not merely a rubber stamp for decisions made by PPC's U.S. management. We recommend that C&H assist with the identification and vetting of suitable candidates, in coordination with PBI's existing management and PPC's general counsel.
D. DEMPE Documentation
C&H recommends that PPC and PBI prepare an annual DEMPE matrix allocating each DEMPE function between PPC and PBI for each product line. During the Examination, the DEMPE matrix prepared by C&H (in coordination with Whitmore) was introduced as part of PPC's defense at the Appeals stage and was instrumental in demonstrating that PBI performs meaningful DEMPE functions. However, this matrix was prepared retrospectively for litigation-defense purposes rather than on a contemporaneous basis. Going forward, the DEMPE matrix should be prepared annually as part of the transfer pricing documentation cycle and should be incorporated into Crestfield's annual report.
The DEMPE matrix should cover each of PPC's principal products (Veritaxol, Imvara, Cerulon, and any new products entering the portfolio) and should address each DEMPE function with the following level of specificity:
Development. PBI's contributions to clinical development activities outside the Americas should be documented in detail. This includes regulatory submissions prepared or coordinated by PBI (including centralized EU submissions through the European Medicines Agency and national submissions in other non-Americas jurisdictions), Phase IV post-marketing studies conducted by or on behalf of PBI, regional clinical trials designed to support non-Americas regulatory requirements or commercial strategies, and any PBI-managed or PBI-funded research collaborations with non-Americas academic institutions or contract research organizations. The documentation should quantify PBI's development expenditures and identify the PBI personnel responsible for overseeing development activities.
Enhancement. PBI's role in product lifecycle management should be documented, including formulation adaptations for non-Americas markets (e.g., different dosage forms, packaging configurations, or labeling requirements), label extensions pursued by PBI to expand the approved indications in non-Americas jurisdictions, and any product improvements or modifications driven by PBI's non-Americas commercial insights. This function was relatively underdocumented during the Examination period and should receive enhanced attention going forward.
Maintenance. PBI's management of regulatory compliance, pharmacovigilance, and quality assurance for the non-Americas supply chain should be documented, including PBI's oversight of PMI's contract manufacturing operations. PBI's pharmacovigilance function — including adverse event reporting, periodic safety update reports, and risk management plans submitted to non-Americas regulatory authorities — represents a significant DEMPE function that was effectively demonstrated during the Examination but should be more comprehensively documented on a contemporaneous basis.
Protection. PBI's role in IP protection should be documented, including patent prosecution and defense in non-Americas jurisdictions, trademark registration and enforcement, trade secret protection, and anti-counterfeiting efforts. This was an area where the IRS found PPC U.S. personnel playing a disproportionate role during the Examination period. Specifically, the IRS noted that patent prosecution and enforcement decisions in non-Americas jurisdictions were substantially directed by PPC's U.S.-based legal department, with PBI's involvement limited to administrative coordination. Going forward, PBI should take a more active role in IP protection outside the Americas, either by hiring in-house IP counsel in Ireland or by engaging and directly managing outside IP counsel in non-Americas jurisdictions, with PBI's Managing Director or a designated PBI officer retaining decision-making authority over IP protection strategy for PBI's territories.
Exploitation. PBI's commercial activities — marketing, pricing, distribution, and sales — across 68 country markets outside the Americas represent the most visible and most easily documented DEMPE function. The documentation should describe PBI's commercial organization, its marketing and promotional activities (including digital marketing, medical education, key opinion leader engagement, and conference participation), its pricing and market access strategy, and its distribution and logistics arrangements.
E. Capital Expenditure and Infrastructure
PBI's cumulative regulatory expenditures of €47.2 million during TY 2017–2020 were meaningful evidence of substance during the Examination. C&H recommends that PBI continue to invest in its operational infrastructure to maintain and strengthen its substance profile:
Regulatory Infrastructure. PBI should continue to invest in regulatory submissions and dossier management for non-Americas markets. This includes not only the direct costs of regulatory submissions (filing fees, clinical data packages, expert reports) but also the internal infrastructure necessary to manage a complex multi-market regulatory portfolio (regulatory information management systems, document management platforms, training programs).
IT Infrastructure. PBI should maintain IT infrastructure and enterprise systems that are either separate from or independently operated vis-à-vis PPC's U.S.-based systems. During the Examination, the IRS noted that PBI's email, ERP, and CRM systems were hosted on PPC's global IT platform, which the IRS argued was evidence of PBI's dependence on PPC. While shared IT platforms are common and not inherently problematic, PBI should ensure that it has the ability to independently access, manage, and control its own data and systems, and should document any service-level agreements or IT intercompany arrangements that govern the shared platform.
Office Space. PBI's office space should be appropriate for its growing headcount and should reflect the operational scale of a significant pharmaceutical entity. The current approximately 18,000 square feet at Sandyford Business Park may need to be expanded as PBI's headcount grows.
Professional Services. PBI should continue to engage and manage local professional services providers — including legal counsel, regulatory consultants, tax advisors, and commercial consultants — from Ireland. These engagements should be initiated and managed by PBI personnel, not by PPC's U.S.-based teams, and the invoices, engagement letters, and deliverables should be addressed to PBI and paid from PBI's bank accounts.
F. Banking and Treasury Operations
PBI's banking relationship with Glenmore Bank Ireland plc was important evidence of PBI's independent treasury operations during the Examination. C&H recommends maintaining robust local banking activities, including:
Separate Bank Accounts. PBI should maintain separate bank accounts for revenue collection, disbursements, and intercompany settlements. Revenue from non-Americas customers should flow directly into PBI's accounts, not through PPC's U.S. accounts.
Independent Treasury Function. PBI's treasury function should make independent cash-management decisions, including decisions regarding short-term investment of surplus funds, management of working capital, and timing of intercompany settlements. These decisions should not be directed by PPC's U.S. treasury department, although PPC may provide advice or guidelines under a properly documented intercompany services arrangement.
Documentation of Treasury Activities. PBI should periodically document its working capital management practices and any hedging activities (e.g., foreign currency hedging for non-EUR revenue streams), including the decision-making process and the identity of the PBI personnel responsible for treasury operations. This documentation should be maintained in the transfer pricing document repository.
VI. Recommendations — Intercompany Agreement Maintenance
A. CSA Agreement
The CSA, originally executed effective July 1, 2012, should be reviewed and, if appropriate, amended to ensure that it reflects current regulatory standards u